secwatch.observer — SEC 8-K summary
======================================

Issuer:     Autolus Therapeutics plc (AUTL)
CIK:        0001730463
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001730463-25-000064
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Autolus reports Q2 AUCATZYL revenue $20.9M; EU/UK approvals secured but Germany launch on hold
--------------------------------------------------------------------------------

- Net product revenue $20.9M in Q2, $29.9M H1 2025; 46 U.S. centers activated, >90% medical lives covered.
- UK MHRA (Apr 25) and EC (Jul 17) conditional approvals granted for AUCATZYL in r/r B-ALL.
- NICE preliminary ACD recommended against funding; EU launch paused, no sales expected in 2025-2026.
- Cash $454.3M (Jun 30 vs $588.0M Dec 31); net loss $47.9M (Q2 2025) vs $58.3M (Q2 2024).
- Pipeline: obe-cel Phase 2 LN trial and Phase 1 MS trial first patient dosing by year-end 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730463/000173046325000064/0001730463-25-000064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730463/000173046325000064/autl-20250812.htm
  HTML page:      https://secwatch.observer/filing/0001730463-25-000064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer